局部晚期直肠癌全程新辅助治疗后的生活质量与晚期毒性:LARCT-US研究
LARCT-US前瞻性研究纳入273例局部晚期直肠癌患者,接受短程放疗(5×5 Gy)序贯4周期CAPOX或6周期mFOLFOX-6,另纳入189例类似治疗患者。治疗三年后生活质量评估显示总体健康状况和功能评分较高,但LARS发生率79%(其中47%为重度),3年及5年≥3级晚期毒性分别为12%和8%。
要点
- 缩短版TNT方案(LARCT-US)肿瘤学结果良好,晚期毒性风险低,生活质量可接受。
- LARS发生率高达79%,其中47%为重度LARS。
- 3年≥3级晚期毒性12%,5年8%;出现晚期毒性者生活质量多项评分更差。
核心结论
- 缩短版TNT方案(LARCT-US)与RAPIDO研究相比,肿瘤学结果良好、晚期毒性风险低,生活质量与其他效果较差的新辅助治疗相似且可接受。
研究设计与样本
- 前瞻性LARCT-US研究纳入16家瑞典医院的273例局部晚期直肠癌患者,接受短程放疗(5×5 Gy)序贯4周期CAPOX或6周期mFOLFOX-6。
- 另纳入189例接受类似治疗的患者(ad modum LARCT-US,AdmL)。
- 采用EORTC QLQ-C30、QLQ-CR29评估治疗三年后生活质量,LARS-score评估肠道功能,随访3年和5年记录医生报告的≥3级晚期毒性。
主要发现
- LARCT-US治愈性治疗且无复发患者中,144/176(82%)纳入生活质量评估。
- 总体健康状况评分和所有功能评分均较高(均值分别为73和约86)。
- 最常报告的症状为腹胀、尿频和疲乏。
- LARS发生率为79%(n=42/53),其中47%为重度LARS。
- LARCT-US/AdmL患者≥3级晚期毒性3年发生率为12%(n=33/265),5年为8%(n=16/254)。
临床怎么用
- 缩短版TNT方案可用于局部晚期直肠癌,需关注晚期毒性及LARS对生活质量的影响。
- 治疗后3年及5年应监测≥3级晚期毒性,出现毒性者需评估生活质量相关症状。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Total neoadjuvant therapy (TNT) is increasingly used to treat locally advanced rectal cancer (LARC) due to more complete responses and fewer systemic recurrences. However, its impact on quality-of-life (QoL) or late toxicity remains under-investigated. This study evaluates this in a large real-world Swedish cohort treated with an abbreviated RAPIDO-TNT-protocol (LARCT-US). MATERIAL AND METHODS: In the prospective LARCT-US study, 273 LARC patients from 16 Swedish hospitals received short-course radiotherapy (5x5 Gy) followed by four cycles of CAPOX (or six cycles of mFOLFOX-6). An additional 189 patients who received similar treatment were included (ad modum LARCT-US, AdmL). QoL was assessed three years post-treatment using EORTC QLQ-C30, QLQ-CR29 and bowel function using the LARS-score. Physician-reported grade 3+ late toxicity was recorded at three- and five-years follow-up. RESULTS: Of curatively treated recurrence-free LARCT-US patients, 144/176 (82%) were included in the QoL assessment. Global health score (GHS) and all functioning scores were high (mean 73 and ∼86, respectively). Flatulence, urinary frequency, and fatigue were the most commonly reported symptoms. LARS was present in 79% of patients (n = 42/53), with 47% experiencing major LARS. Grade 3+ late toxicity occurred in 12% (n = 33/265) of LARCT-US/AdmL patients after three years and in 8% (n = 16/254) after five years. Patients with late toxicity reported worse scores for GHS, fatigue, dysuria, financial difficulties, and role and social functioning. CONCLUSIONS: An abbreviated TNT schedule, compared with the RAPIDO-study, used in LARCT-US, achieves favourable oncological outcomes with low risk of late toxicity, and an acceptable QoL similar to other less effective neoadjuvant treatments.
引用
- Imam I, Khan T, Nilsson PJ, et al. Quality of life and late toxicity after total neoadjuvant treatment for locally advanced rectal cancer - LARCT-US. Radiother Oncol. 2025. PMID: 41319717. doi:10.1016/j.radonc.2025.111318
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。